BNP Paribas Financial Markets
GTBP icon

BNP Paribas Financial Markets’s GT Biopharma GTBP Stock Holding History

BNP Paribas Financial Markets’s Portfolio GTBP Stock Details GTBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3 Sell
6
-10
-63% -$4 ﹤0.01% 5886
2026
Q1 		$7 Hold
16
– – ﹤0.01% 5772
2025
Q4 		$13 Hold
16
– – ﹤0.01% 5685
2025
Q3 		$9 Hold
16
– – ﹤0.01% 5521
2025
Q2 		$57 Buy
16
+10
+167% +$26 ﹤0.01% 5350
2025
Q1 		$13 Hold
6
– – ﹤0.01% 5332
2024
Q4 		$18 Hold
6
– – ﹤0.01% 5353
2024
Q3 		$14 Hold
6
– – ﹤0.01% 4110
2024
Q2 		$17 Hold
6
– – ﹤0.01% 4012
2024
Q1 		$27 Buy
+6
New +$32 ﹤0.01% 3992

Other funds holding GTBP

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
EFG
Everhart Financial Group Dublin, Ohio $1.56B AUM 34.29% 1-Year Est. Return
AAP
Arax Advisory Partners Denver, Colorado $15.1B AUM 27.93% 1-Year Est. Return
OWA
Opal Wealth Advisors Jericho, New York $463M AUM 20.47% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
4WM
49 Wealth Management Austin, Texas $524M AUM 16.59% 1-Year Est. Return
Cetera Investment Advisers
Cetera Investment Advisers Schaumburg, Illinois $110B AUM 26.29% 1-Year Est. Return
SWM
SeaCrest Wealth Management Purchase, New York $903M AUM 47.26% 1-Year Est. Return

BNP Paribas Financial Markets's GTBP Position: Q2 2026 in Review

BNP Paribas Financial Markets reduced its GT Biopharma (GTBP) stake by 63% in Q2 2026, selling an estimated $4 and leaving 6 shares worth $3. The position accounts for ﹤0.01% of the portfolio, ranked #5886.

BNP Paribas Financial Markets first reported a position in GTBP in Q1 2024 and has held it in 10 quarters since. The position peaked at $57 in Q2 2025. 47 funds tracked by Wall St. Rank hold GTBP as of Q2 2026.

  • BNP Paribas Financial Markets held 6 shares of GT Biopharma worth $3 as of Q2 2026.
  • BNP Paribas Financial Markets sold 10 GT Biopharma shares in Q2 2026, an estimated $4.
  • GT Biopharma made up ﹤0.01% of BNP Paribas Financial Markets's portfolio in Q2 2026, its #5886 holding.
  • BNP Paribas Financial Markets first reported a position in GT Biopharma in Q1 2024 and has held it in 10 quarters since.
  • BNP Paribas Financial Markets's GT Biopharma position peaked at $57 in Q2 2025.
  • 47 funds tracked by Wall St. Rank held GT Biopharma as of Q2 2026.

Based on BNP Paribas Financial Markets's 13F filing for Q2 2026, filed 13 Aug 2026.